Transcript Siemens One

Flexible manufacturing for vaccines –
helping Novartis Vaccines to improve competitiveness
EUR 2.3 M
project value
• Novartis Vaccines is the world's fifthlargest vaccines business and the
world's second-largest manufacturer of
flu vaccines and has important
meningococcal, pediatric and travel
vaccine franchises. The company's
portfolio of products includes vaccines
for influenza, meningitis, rabies, tickborne encephalitis, Haemophilus
influenzae B (Hib), polio, mumps,
measles and rubella and diphtheria,
tetanus and pertussis (whooping
cough).
•The site at Liverpool, which has a long
history, was selected for a major
investment to develop a state-of-the-art
manufacturing facility for flexible vaccine
production. The new building is known
as ‘Site 4’.
Page 1
Feb-06
Solutions implemented:
 PCS-7 batch-based process control system
 Motor controls, UPS, weighing system
 Building management system
 A&D S7 PLCs specified to all 3rd party equipment suppliers
Siemens Groups involved:
 A&D & SBT
 Future potential for A&D, SBT and Enterprise
Project goal:
 Initially, to increase the output and quality of flu vaccine production.
 In the long term, Site 4 will be Novartis’s main site for the production of
egg-based vaccines
Value to customer:
 Siemens has worked as a team with Novartis and the engineering
contractor, CEL International, to ensure that Site 4 will be capable of
meeting its quality and production requirements
 Understanding Novartis’s business drivers has been a key factor
The future:
 Expansion of the initial facility is planned, with significant A&D potential
 Enterprise are in discussions with Novartis Vaccines regarding global
voice and data requirements
 SBT are also in discussions regarding managed security on site
Siemens success stories – Internal Use Only
CD SO
Back-up Information
Siemens GBR: Chiron Vaccines Limited
Customer Information




Customer Name:
Novartis Vaccines & Diagnostics Limited
Location:
Liverpool / UK
Siemens Contact Persons:
Harald / Rueckl / [email protected]
Project completion:
First phase completion March 2007
Organizational Topics





Cleared for external use:
no
Use of picture and logo:
no
Existing material:
Internal presentation attached
Sector/solution:
Pharmaceutical
Further notes…
Page 2
Feb-06
Siemens success stories – Internal Use Only
CD SO